Hemophagocytic lymphohistiocytosis with MUNC13-4 gene mutation or reduced natural killer cell function prior to onset of childhood leukemia
dc.contributor.author | Chang, Tamara Y. | |
dc.contributor.author | Jaffray, Julie | |
dc.contributor.author | Woda, Bruce A. | |
dc.contributor.author | Newburger, Peter E. | |
dc.contributor.author | Usmani, G. Naheed | |
dc.date | 2022-08-11T08:10:10.000 | |
dc.date.accessioned | 2022-08-23T16:58:16Z | |
dc.date.available | 2022-08-23T16:58:16Z | |
dc.date.issued | 2010-12-15 | |
dc.date.submitted | 2012-04-25 | |
dc.identifier.citation | 2010 Dec 15. <a href="http://dx.doi.org/10.1002/pbc.22846">Link to article on publisher's website</a> | |
dc.identifier.issn | 1545-5009 (Linking) | |
dc.identifier.doi | 10.1002/pbc.22846 | |
dc.identifier.pmid | 21370424 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/43331 | |
dc.description.abstract | Hemophagocytic lymphohistiocytosis (HLH) is a rare histiocytic reactive process due to mutations in the perforin, MUNC13-4 or syntaxin 11 genes, or secondary to malignancy, infection or autoimmune disorder. HLH as a preceding diagnosis to leukemia is rare. We report two cases with progression to acute leukemia, one heterozygous for MUNC13-4 and the other with reduced natural killer (NK) cell function and perforin expression. These defects may predispose to a secondary HLH-like presentation of pre-clinical leukemia or confer increased susceptibility to malignancy. HLH patients with genetic mutations or NK cell function abnormalities need monitoring for future malignancy even if the HLH resolves. | |
dc.language.iso | en_US | |
dc.relation | <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21370424&dopt=Abstract">Link to article in PubMed</a> | |
dc.relation.url | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059114/pdf/nihms234116.pdf | |
dc.subject | Child, Preschool | |
dc.subject | Female | |
dc.subject | Heterozygote | |
dc.subject | Humans | |
dc.subject | Killer Cells, Natural | |
dc.subject | Leukemia, Monocytic, Acute | |
dc.subject | Lymphohistiocytosis, Hemophagocytic | |
dc.subject | Membrane Proteins | |
dc.subject | Mutation | |
dc.subject | Perforin | |
dc.subject | Precursor Cell Lymphoblastic Leukemia-Lymphoma | |
dc.subject | Prognosis | |
dc.subject | Qa-SNARE Proteins | |
dc.subject | Hematology | |
dc.subject | Oncology | |
dc.subject | Pediatrics | |
dc.title | Hemophagocytic lymphohistiocytosis with MUNC13-4 gene mutation or reduced natural killer cell function prior to onset of childhood leukemia | |
dc.type | Journal Article | |
dc.source.journaltitle | Pediatric blood and cancer | |
dc.source.volume | 56 | |
dc.source.issue | 5 | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/peds_hematology/133 | |
dc.identifier.contextkey | 2796624 | |
html.description.abstract | <p>Hemophagocytic lymphohistiocytosis (HLH) is a rare histiocytic reactive process due to mutations in the perforin, MUNC13-4 or syntaxin 11 genes, or secondary to malignancy, infection or autoimmune disorder. HLH as a preceding diagnosis to leukemia is rare. We report two cases with progression to acute leukemia, one heterozygous for MUNC13-4 and the other with reduced natural killer (NK) cell function and perforin expression. These defects may predispose to a secondary HLH-like presentation of pre-clinical leukemia or confer increased susceptibility to malignancy. HLH patients with genetic mutations or NK cell function abnormalities need monitoring for future malignancy even if the HLH resolves.</p> | |
dc.identifier.submissionpath | peds_hematology/133 | |
dc.contributor.department | Department of Pathology | |
dc.contributor.department | Department of Pediatrics | |
dc.source.pages | 856-8 |